PharmaJet to Showcase Advantages of Needle-Free Intradermal Delivery at Medical Conference in Ethiopia
PharmaJet®, a company dedicated to enhancing the performance and outcomes of injectables through its innovative technology, has announced its participation in the 61st Annual Medical Conference and International Health Exhibition. The event will take place on February 21-22, 2025, at the Haile Grand in Addis Ababa, Ethiopia. At the conference, PharmaJet will present the latest findings from its routine immunization study. Paul LaBarre, Vice President of Global Business Development at PharmaJet, will deliver a presentation titled “Intradermal Needle-Free Vaccine Delivery to Reduce Ethiopia’s Immunization Costs and Improve Coverage.” This prestigious gathering will host physicians from across Ethiopia, representatives from the Ethiopian Medical Association chapter offices, medical specialty societies, medical schools, the Ministries of Health (MoH) and Education, as well as professionals from partner organizations.
The focus of PharmaJet’s presentation will be on how intradermal (ID) vaccine administration can serve as a transformative approach to immunization. This method has the potential to enhance cross-protection, extend the duration of immune response, and improve mucosal immunity. Historically, ID vaccine administration has posed challenges due to the complexity of traditional needle and syringe methods. However, the introduction of the PharmaJet Tropis® ID System has simplified this process by enabling needle-free ID delivery, offering greater efficiency and broader acceptance among healthcare providers and patients alike.
PharmaJet’s needle-free Tropis system has already been used extensively, particularly in global polio immunization campaigns. To date, it has facilitated the administration of polio vaccinations to over 10 million children worldwide. Notably, Tropis is the first and only needle-free ID delivery technology to receive prequalification from the World Health Organization (WHO), marking a significant milestone in vaccine delivery technology.
The benefits of PharmaJet’s technology have been demonstrated through a recent randomized controlled implementation study conducted in Nigeria. The study aimed to assess the impact of needle-free intradermal fractional inactivated poliovirus vaccine (fIPV) delivery using Tropis compared to the conventional standard of care (SoC) involving full-dose intramuscular IPV delivery via needle and syringe. The study provided compelling evidence of the advantages of needle-free administration, including:
- Enhanced Coverage: The results showed an 11.2% increase in IPV2 coverage among those vaccinated with the Tropis system compared to the standard of care. This improvement indicates a potential for broader vaccine reach and higher immunization rates.
- Cost Reduction: The study highlighted significant cost savings associated with Tropis. The incremental savings per dose administered ranged from $0.07 to $1.00 across different scenarios. At full scale, total immunization cost savings of up to 47% were observed when using the needle-free system instead of traditional methods.
- High Acceptability: Caregivers and healthcare workers expressed a strong preference for the Tropis system. A remarkable 94% of caregivers reported high satisfaction with the needle-free method, while 95% of healthcare workers favored Tropis over traditional needle and syringe administration. Furthermore, Tropis reduced vaccine administration time by an average of five seconds per dose compared to the conventional approach.
Paul LaBarre, Vice President of Global Business Development at PharmaJet, emphasized the transformative potential of Tropis for routine immunization programs. “The Nigeria study results demonstrate how using Tropis for routine immunization programs can provide significant benefits at all levels of the healthcare system,” he stated. “By leveraging evidence from successful Tropis deployments in Pakistan, Somalia, and Nigeria, we are eager to collaborate with the Ethiopian Ministry of Health and other African partners to explore how needle-free ID delivery can optimize their immunization programs.”
The findings from Nigeria align with previous research and real-world applications that have demonstrated the efficacy and efficiency of needle-free vaccine delivery. Countries such as Pakistan and Somalia have also integrated Tropis into their immunization campaigns, further validating its potential as a game-changing technology in the fight against infectious diseases. The ability of Tropis to enhance coverage while reducing costs makes it particularly relevant in resource-limited settings where optimizing healthcare expenditures is crucial.
Beyond its role in polio immunization, needle-free vaccine administration holds promise for broader applications in public health. ID vaccine delivery has been shown to generate robust immune responses with lower antigen doses, potentially expanding vaccine supply and improving overall immunization coverage. As global health organizations continue to seek innovative solutions to immunization challenges, technologies such as PharmaJet’s Tropis system offer a pathway toward more efficient, cost-effective, and widely accepted vaccine administration methods.
The 61st Annual Medical Conference and International Health Exhibition will provide an invaluable platform for discussing the latest advancements in healthcare and immunization strategies. PharmaJet’s participation underscores its commitment to advancing vaccine delivery through cutting-edge technology. By engaging with key stakeholders from the Ethiopian healthcare system and beyond, PharmaJet aims to further the adoption of needle-free vaccine administration in routine immunization programs.
Conference attendees will have the opportunity to learn more about PharmaJet’s innovative technology by visiting their booth in the exhibition area. Additionally, interested parties can explore further details about the Tropis system and its applications by visiting PharmaJet’s official website at https://pharmajet.com.
As Ethiopia and other nations continue to strengthen their immunization efforts, the integration of advanced delivery systems like Tropis could play a pivotal role in achieving global vaccination goals. By reducing the barriers associated with traditional needle-based administration, improving vaccine coverage, and lowering costs, needle-free technology represents a significant step forward in modern healthcare. PharmaJet’s ongoing research and commitment to innovation position it as a leader in the field of vaccine delivery, with the potential to make a lasting impact on public health worldwide
